Pratik Chandrani
Overview
Explore the profile of Pratik Chandrani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
337
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shah M, Noronha V, Patil V, Singh A, Menon N, Goud S, et al.
Clin Lung Cancer
. 2025 Mar;
PMID: 40050197
Background: The utility of Next-Generation-Sequencing (NGS) in patients of non-small-cell-lung-cancer (NSCLC) has led to an exponential increase in the identification of driver-gene alterations, however, Indian NGS data was lacking. Materials...
2.
Khuntia S, Mukherjee N, Javle V, Tanwar N, Sreekanthreddy P, Varghese L, et al.
JCO Glob Oncol
. 2024 Nov;
10:e2400289.
PMID: 39571115
Purpose: Gene fusions are critical oncogenic mutations that drive cancer development and serve as diagnostic and prognostic biomarkers. Despite the increasing cancer burden in India, large-scale analyses of molecular landscapes,...
3.
Noronha V, Budukh A, Chaturvedi P, Anne S, Punjabi A, Bhaskar M, et al.
Lancet Reg Health Southeast Asia
. 2024 Aug;
27:100430.
PMID: 39157507
Lung cancer varies between Caucasians and Asians. There have been differences recorded in the epidemiology, genomics, standard therapies and outcomes, with variations according to the geography and ethnicity which affect...
4.
Prabhash K, Saldanha E, Patil V, Bal M, Reddy P S, Sanjeev A, et al.
JCO Precis Oncol
. 2024 May;
8:e2300622.
PMID: 38754058
Purpose: Medullary thyroid cancer (MTC) is a rare cancer originating from parafollicular C cells of the thyroid gland. Therapeutically relevant alterations in MTC are predominantly reported in oncogene, and lower-frequency...
5.
Noronha V, Sarkar L, Patil V, Menon N, Shah M, Pawar A, et al.
Ecancermedicalscience
. 2024 Mar;
18:1674.
PMID: 38439805
Objectives: Kirsten rat sarcoma viral oncogene homologue () mutations in lung cancers, long considered untargetable, have had a recent rise in interest due to promising data of agents targeting p.G12C....
6.
Gardi N, Chaubal R, Parab P, Pachakar S, Kulkarni S, Shet T, et al.
Cancer Res Commun
. 2024 Feb;
4(2):404-417.
PMID: 38315150
Significance: In germline BRCA1 mutated and BRCA wild-type patients, TNBC shows a branching evolutionary pattern of mutations with a single founding clone, are polyclonal throughout their disease course, and have...
7.
Tanwar N, Malhotra R, Satheesh A, Khuntia S, Sreekanthreddy P, Varghese L, et al.
JCO Glob Oncol
. 2023 Dec;
9:e2300047.
PMID: 38085046
Purpose: The purpose of this study was to understand the impact of population diversity and geographic variation on tumor mutation burden (TMB) scores across cancers and its implication on stratification...
8.
Chougule A, Chandrani P, Noronha V, Pange P, Kale S, Nikam A, et al.
JTO Clin Res Rep
. 2023 Nov;
4(11):100566.
PMID: 38033811
The significance of EGFR targeted therapy in the lung adenocarcinoma is paramount. Several controlled clinical trials have reported considerable survival of EGFR mutation positive patients on receiving the EGFR tyrosine...
9.
Trivedi V, Noronha V, Sreekanthreddy P, Desai S, Poojary D, Varghese L, et al.
Front Endocrinol (Lausanne)
. 2023 Nov;
14:1152514.
PMID: 38027096
Introduction: The diverse subtypes of thyroid carcinoma have distinct clinical outcomes despite a comparable spectrum of underlying genetic alterations. Beyond genetic alterations, sparse efforts have been made to characterize the...
10.
Sambath J, Noronha V, Manda S, Mishra R, Chandrani P, Patil V, et al.
Gene
. 2023 Nov;
893:147952.
PMID: 37918550
Objectives: The aim of this pilot study is to identify the genetic factors that contribute to the response of metronomic chemotherapy in head and neck squamous cell carcinoma (HNSCC) patients...